AN2718 has demonstrated in preclinical studies that it has activity against fungal strains that cause infection of the skin and nail. The compound utilizes the same mechanism as AN2690, our lead topical product candidate for the treatment of onychomycosis. AN2718 appears to be well suited to target organisms that cause common skin and topical fungal infections, including trichophyton and candida fungi.